ACM Research Inc vs Cronos Group Inc — how do they compare? ACM Research Inc trades at $81.11 (market cap $5.53B), while Cronos Group Inc trades at $3.08 (market cap $1.11B). The key difference: ACM Research Inc is far larger — about 5× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, ACM Research Inc nearer its low. Which is the better fit depends on your goals.
| ACMR | CRON | |
|---|---|---|
Market Cap | $5.53B | $1.11B |
Sector | Technology | Health |
52-Week High | $126.89 | $3.27 |
52-Week Low | $24.93 | $2.30 |
Enterprise Value | $4.44B | $310.67M |
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $83.80, up 6.1% in the last session, with strong technical momentum above key support at $77. Recent Q2 2026 earnings beat expectations with EPS of $0.61 versus $0.42 expected, while revenue grew 36% year-over-year. The company raised 2026 guidance amid accelerating orders and new product expansion, supporting a bullish analyst consensus with 80% buy ratings and a $127.50 price target.
Outlook remains positive given earnings momentum and raised guidance, but risks include high valuation (P/E 37.5), margin pressure from rising expenses, and dependence on semiconductor cycle. The stock offers growth exposure but requires monitoring of execution against elevated expectations.
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
Trailing returns across standard periods
Latest headlines on both assets
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →